(Il Sole 24 Ore Radiocor) – Rome, April 07 – The Indian group Sun Pharmaceutical Industries has announced the acquisition of the shares of the struggling rival group Ranbaxy becoming the Indian number one and the world number five in the generic drugs sector. Sun Pharma, explains a note, will pay everything in shares and Ranbaxy shareholders will receive 0.8 Sun Pharma shares for every Ranbaxy share.
Daiichi Sankyo, the Japanese group majority shareholder of Ranbaxy since 2008, will become a "significant" shareholder in the new entity, with a 9 percent stake.
On a like-for-like basis, the new group will have revenues of $4.2 billion for an ebitda of $1.2 billion in 2013. It is present in 65 countries and will feature 47 plants on five continents.
Related news: https://www.fedaiisf.it/Start/HDefault.aspx?Newsid=8850
